Network pharmacology and experimental verification in vivo reveal the mechanism of Zhushao Granules against ulcerative colitis

被引：0
作者：
Gong, Benjiao [1 ]
Zhang, Chenglin [1 ]
Hu, Shaofei [2 ]
Zhang, Xueying [3 ]
Zou, Hui [4 ]
Li, Jiayao [1 ]
Wang, Jiahui [1 ]
Kao, Yanlei [4 ]
Liu, Fujun [1 ]
机构：
[1] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Cent Lab, Yantai, Peoples R China
[2] Qingdao Univ, Yantai Yuhuangding Hosp Affiliated, Dept Pharm, Yantai, Peoples R China
[3] Shandong Second Med Univ, Life Sci & Technol Coll, Weifang, Peoples R China
[4] Yantai Hosp Tradit Chinese Med, Dept Spleen & Stomach Dis, Yantai, Peoples R China
来源：
BIOLOGICAL PROCEDURES ONLINE | 2025年 / 27卷 / 01期
关键词：
Zhushao granules; Ulcerative colitis; Network pharmacology; ZBP1/RIP/NF-kappa B pathway; INNATE IMMUNE-RESPONSES; DAI DLM-1/ZBP1; ELLAGIC ACID; T-CELLS; INFLAMMATION; RECEPTOR; INTERFERON; ACTIVATOR; TARGETS; MODELS;
D O I：
10.1186/s12575-025-00268-3
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
BackgroundZhushao Granules (ZSG) had exhibited beneficial effects in the treatment of ulcerative colitis (UC) as an effective herbal prescription in Traditional Chinese Medicine. However, the underlying anti-inflammatory mechanism of ZSG remains unclear. This study aimed to decipher the mechanism of ZSG against UC combining network pharmacology and animal-based experiments.MethodsNetwork pharmacology was employed to identify active components and therapeutic targets of ZSG against UC. The protein-protein interaction (PPI) network was constructed among the therapeutic targets using the STRING database, and GO and pathway analyses were carried out using DAVID. Then, the "herb-component-target-pathway" network based on therapeutic targets was established and the topological parameters were subsequently calculated to identify hub active components, targets and pathways by Cytoscape. Finally, the therapeutic function and the special pathway of ZSG against UC were validated using a TNBS-induced UC model in BABL/c mice.ResultsNinety-four active components of ZSG and 460 potential targets were acquired from the Encyclopedia of Traditional Chinese Medicine and Tradition Chinese Medicine Systems Pharmacology Database and Analysis Platform. 884 potential targets of UC were obtained from OMIM and HINT. Sixty-two overlapping potential targets were identified as therapeutic targets of ZSG against UC. PPI network filtered out 61 therapeutic targets. GO and pathway analyses extracted 48, 25, and 98 terms corresponding to biological processes, molecular functions and Reactome pathways, respectively. Enrichment analysis suggested that the therapeutic targets were mainly involved in immune regulation, especially RIP-mediated NF-kappa B activation via ZBP1. Topological analysis of the "herb-component-target-pathway" network recognized 9 hub components, 20 hub targets and 18 hub pathways. The animal-based experiments revealed that ZSG ameliorated symptoms and histological changes in TNBS-induced colitis by significantly inhibiting the ZBP1/RIP/NF-kappa B pathway.ConclusionsZSG might alleviate the mucosal damage and ameliorate colitis via targeting ZBP1/RIP/NF-kappa B pathway, which laid the theoretical foundation for the clinical application and further study of ZSG and provided new insights into UC treatment.
引用
收藏
页数：14
相关论文
共 70 条
  • [1] Ungaro R., Mehandru S., Allen P.B., Peyrin-Biroulet L., Colombel J.F., Ulcerative colitis, Lancet, 389, pp. 1756-1770, (2017)
  • [2] Rubin D.T., Ananthakrishnan A.N., Siegel C.A., Sauer B.G., Long M.D., ACG Clinical Guideline: Ulcerative Colitis in Adults, Am J Gastroenterol, 114, 3, pp. 384-413, (2019)
  • [3] Ananthakrishnan A.N., Bernstein C.N., Iliopoulos D., Macpherson A., Neurath M.F., Ali R.A.R., Et al., Environmental triggers in IBD: a review of progress and evidence, Nat Rev Gastroenterol Hepatol, 15, 1, pp. 39-49, (2018)
  • [4] Olen O., Erichsen R., Sachs M.C., Pedersen L., Halfvarson J., Askling J., Et al., Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study, Lancet, 395, pp. 123-131, (2020)
  • [5] Caruso R., Lo B.C., Nunez G., Host-microbiota interactions in inflammatory bowel disease, Nat Rev Immunol, 20, 7, pp. 411-426, (2020)
  • [6] Kobayashi T., Siegmund B., Le Berre C., Wei S.C., Ferrante M., Shen B., Et al., Ulcerative colitis, Nat Rev Dis Primers, 6, 1, (2020)
  • [7] Binienda A., Fichna J., Salaga M., Recent advances in inflammatory bowel disease therapy, Eur J Pharma Sci, 155, (2020)
  • [8] Cross R.K., Lapshin O., Finkelstein J., Patient subjective assessment of drug side effects in inflammatory bowel disease, J Clin Gastroenterol, 42, 3, pp. 244-251, (2008)
  • [9] Rogler G., Gastrointestinal and liver adverse effects of drugs used for treating IBD, Best Pract Res Clin Gastroenterol, 24, 2, pp. 157-165, (2010)
  • [10] Liang X., Li H., Li S., A novel network pharmacology approach to analyse traditional herbal formulae: the Liu-Wei-Di-Huang pill as a case study, Mol BioSyst, 10, 5, pp. 1014-1022, (2014)
1234567